Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Raman, G.
Right arrow Articles by Wilkinson, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raman, G.
Right arrow Articles by Wilkinson, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 14, Issue 2 384-388, Copyright © 1999 by Oxford University Press

ORIGINAL ARTICLES

Renal effects of amlodipine in normotensive renal transplant recipients

G Raman, J Feehally, R Coates, H Elliott, P Griffin, J Olubodun and R Wilkinson
St Mary's Hospital, Milton Road, Portsmouth PO3 6AD, UK; Leicester General Hospital, Leicester, UK; Western Infirmary, Glasgow, UK; Cardiff Royal Infirmary, Cardiff, UK; Freeman Hospital, Newcastle upon Tyne, UK; Corresponding author

Renal effects of amlodipine in normotensive renal transplant recipients. The use of cyclosporin A (CsA) has improved the success of renal transplantation, but is associated with hypertension and significant renal toxicity. Previous reports suggest that calcium channel blockers may be useful in opposing the adverse effects of CsA. We have evaluated the effects of amlodipine (5 mg, once daily for 8 weeks) on renal function in 27 normotensive renal transplant recipients with stable renal function, in a double-blind, placebo-controlled, multicentre, cross over study. Amlodipine significantly reduced serum creatinine concentration relative to placebo (mean±SD: 168±65 vs 177±66 &mgr;mol/l; P=0.002) and there was a strong trend towards an increase in effective renal plasma flow on amlodipine relative to placebo (238±92 vs 217±87 ml/min; P=0.055). Glomerular filtration rate and lithium clearance were unaffected. Trough CsA blood concentration was unaffected. Amlodipine was well tolerated, with a low incidence of adverse events, and did not affect blood pressure or heart rate. In conclusion, amlodipine reduced serum creatinine in normotensive renal transplant recipients after only 8 weeks treatment, and was well tolerated in concomitant administration with CsA. Key words: amlodipine; cyclosporin A; normotensive; serum creatinine
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
J. Chanard, O. Toupance, S. Lavaud, B. Hurault de Ligny, C. Bernaud, and B. Moulin
Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients
Nephrol. Dial. Transplant., October 1, 2003; 18(10): 2147 - 2153.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.